The FDA cleared the investigational new drug application of IDE849, a potential first-in-class DLL3-targeted antibody-drug ...

including neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and small cell lung cancer (SCLC). Due to its tumor-selective expression profile, SSTR2 has emerged as a promising target ...

into a Phase 1 study in the U.S. DLL3 is upregulated in multiple solid tumor types, including small cell lung cancer (SCLC), neuroendocrine tumors (NETs), non-small cell lung cancer (NSCLC ...

IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new drug (IND) ...

In certain high grade neuroendocrine carcinomas including small cell lung cancer (SCLC), DLL3 is upregulated ... course of any type of pulmonary tumor and often metastasize to other parts of ...

In parallel, we are also exploring opportunities in first-line SCLC and other neuroendocrine tumors to ... to this therapy in China if approved. Tumor Treating Fields (TTFields): In April 2025 ...

ZW171 exhibits strong anti-tumor activity in patient derived xenograft (PDX ... is a cell surface protein overexpressed in small cell lung cancer (SCLC) and other neuroendocrine carcinomas that has ...

DLL3 is an antigen overexpressed in many neuroendocrine tumors, such as SCLC, and is often associated ... called TMALIN®, which leverages the tumor microenvironment to overcome challenges ...

March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoing Over 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM ...

Small-cell lung cancer represents a highly aggressive neuroendocrine subtype of lung cancer. In distant metastatic or ...